Antiproliferative effects of the antiallergic agent azelastine on human aortic smooth-muscle cells: An in vitro study

Investigative Radiology

Volumn 37, Issue 5, 2002, Pages 248-253

  Schöber, Wolfgang ^a   Wiskirchen, Jakub ^a   Kehlbach, Rainer ^a   Gebert, Regina ^a   Rodegerdts, Enno ^a   Betsch, Angelika ^a   Johst, Ursula ^a   Feuls, Roland ^a   Claussen, Claus D ^a   Duda, Stephan H ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Pharmacology; Restenosis; Smooth muscle cell proliferation

Indexed keywords

ANTIALLERGIC AGENT; AZELASTINE;

AORTA MEDIA; ARTICLE; CELL CULTURE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL KINETICS; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS; MITOSIS INHIBITION; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER;

EID: 0036241099     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200205000-00002     Document Type: Article

References (33)

1. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months
2. Fate of patients undergoing transluminal angioplasty for lower-limb ischemia
3. Femoral and popliteal arteries: Reanalysis of results of balloon angioplasty
4. Restenosis after successful coronary angioplasty: Pathophysiology and prevention
5. Kinetics of cellular proliferation after arterial injury
6. Inhibition of neointimal smooth-muscle cell accumulation after angioplasty by an antibody to PDGF
7. Migration of smooth muscle and endothelial cells. Critical events in restenosis
8. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention
9. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits
10. Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat
11. Effectiveness of tranilast on restenosis after directional coronary atherectomy
12. Efficacy of tranilast on restenosis after coronary angioplasty: Is there any rebound phenomenon after ceasing tranilast at 3 months?
13. Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT)
14. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial
15. Azelastine's therapeutic action in asthma
16. In vivo and in vitro H1 antagonist properties of azelastine
17. Migration of smooth muscle and endothelial cells: Critical events in restenosis
18. Anti-allergic properties of a new histamine antagonist, 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl)-(4)-1-(2H)-phthalazinone hydrochloride (azelastine)
19. Azelastine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
20. Effect of azelastine on the release and action of leukotrien C4 and D4
21. Inhibition of cysteinyl-leukotriene production by azelastine and its biological significance
22. The effect of azelastine on neutrophil and eosinophil generation of superoxide
23. Mechanism of inhibitory effects of azelastine on smooth-muscle cell contraction
24. Inhibitory effect of azelastine on protein kinase C and diphosphoinositide kinase in rat mast cells
25. Pharmacological modulation of eosinophil degranulation
26. Inhibition of collagen expression by azelastine hydrochloride in cultured skin fibroblasts from normal individuals and sclerodesmia patients
27. Prospects for site-specific delivery of pharmacologic and molecular therapies
28. Local intra-arterial drug delivery for prevention of restenosis. Comparison of the efficiency of delivery of different radiopharmaceuticals through a porous catheter
29. Localized arterial wall drug delivery from a polymer-coated removable metallic stent: Kinetics, distribution, and bioactivity of forskolin
30. Antiproliferative stent coating: Taxol and related compounds
31. Percutaneous delivery of a heparin-impregnated collagen stent-graft in a porcine model of atherosclerotic disease
32. MR evaluation of stent patency: In vitro tests of 22 metallic stents and the possibility of determining their patency by MR angiograpghy
33. Cyclic x-ray responses in mammalian cells in vitro